Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Novartis jumps into bi-specific antibody space with $150 million Xencor deal
Novartis jumps into bi-specific antibody space with $150 million Xencor deal
Novartis jumps into bi-specific antibody space with $150 million Xencor deal
Submitted by
admin
on June 28, 2016 - 11:14am
Source:
BioPharma Dive
News Tags:
Novartis
bispecific antibodies
Xencor
acute myeloid leukemia
B-cell malignancies
Headline:
Novartis jumps into bi-specific antibody space with $150 million Xencor deal
Do Not Allow Advertisers to Use My Personal information
